Skip to main
PGEN
PGEN logo

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen Inc. has upgraded its GMP facilities to enhance manufacturing capacity ahead of the anticipated launch of PRGN-2012 in the second half of 2025, which positions the company to meet projected demand effectively. Management's proprietary market analysis estimates that PRGN-2012 could generate risk-adjusted revenues of $93 million by 2026, with substantial growth expected to reach $969 million by 2033, indicating a strong market opportunity. Recent adjustments to financial projections, including an increase in the annual price estimate for PRGN-2012 and operational expense adjustments, reflect a commitment to optimizing the company's financial performance ahead of the product's anticipated robust launch.

Bears say

Precigen Inc has faced challenges in establishing reliable revenue streams, as its reliance on collaborations with partners for technology access fees and milestones creates inherent volatility in its income. The company's focus on developing complex synthetic biology solutions has not yet translated into a sustainable or profitable business model, raising concerns about its long-term financial viability. Furthermore, the competitive landscape in the biotechnology sector, coupled with the high costs associated with research and development, contributes to a negative outlook on Precigen's stock performance.

Precigen (PGEN) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 6 analysts, Precigen (PGEN) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.